BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28521029)

  • 1. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
    Meinl E; Krumbholz M
    Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
    Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
    Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
    Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers.
    Mizutani H; Nakane S; Ikeda T; Nakamura H; Takamatsu K; Makino K; Tawara N; Mukaino A; Watari M; Matsui H; Mukasa A; Ando Y
    Ann Clin Transl Neurol; 2018 Dec; 5(12):1611-1616. PubMed ID: 30564626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.
    Kyrtsonis MC; Sarris K; Koulieris E; Maltezas D; Nikolaou E; Angelopoulou MK; Bartzis V; Tzenou T; Dimou M; Siakandaris MP; Viniou NA; Sachanas S; Kalpadakis C; Sfikakis PP; Pangalis GA; Panayiotidis P
    Biomed Res Int; 2014; 2014():159632. PubMed ID: 25162001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies.
    Kersten MJ; Evers LM; Dellemijn PL; van den Berg H; Portegies P; Hintzen RQ; van Lier RA; von dem Borne AE; van Oers RH
    Blood; 1996 Mar; 87(5):1985-9. PubMed ID: 8634448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
    BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Features of Isoforms of Human Soluble TACI.
    Fichtner ML; Rübsamen H; Smolle M; Schaller J; Feederle R; Bültmann A; Kümpfel T; Schneider P; Thaler FS; Meinl E
    J Immunol; 2023 Jul; 211(2):199-208. PubMed ID: 37272840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients.
    Murase S; Saio M; Andoh H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
    Neurol Res; 2000 Jul; 22(5):434-42. PubMed ID: 10935213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
    Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
    Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients.
    Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF
    Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
    Hottinger AF; Iwamoto FM; Karimi S; Riedel E; Dantis J; Park J; Panageas KS; Lassman AB; Abrey LE; Fleisher M; Holland EC; DeAngelis LM; Hormigo A
    Ann Neurol; 2011 Jul; 70(1):163-9. PubMed ID: 21391238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
    Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
    Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.